Reductase inhibitor monotherapy and stroke prevention.
Reductase inhibitor monotherapy and stroke prevention.
复制标题
还原酶抑制剂单一疗法和中风预防。
DOI：
--
复制
发表时间：
1997
影响因子：
--
通讯作者：
C. Furberg
中科院分区：
文献类型：
--
作者：
J. R. Crouse;R. Byington;H. Hoen;C. Furberg
背景
流行病学证据和对早期临床试验数据的荟萃分析表明，降低胆固醇水平并不能减少卒中事件。这些分析没有包括最近使用还原酶抑制剂的临床试验。
目的
在所有报告的使用还原酶抑制剂单药治疗的冠心病一级（n = 4）和二级（n = 8）预防临床试验中，对降低胆固醇水平对卒中的影响进行荟萃分析，并提供卒中事件的信息。
结果
对一级和二级预防试验的综合数据分析显示，使用还原酶抑制剂单药治疗可显著降低卒中发生率（卒中发生率降低27%; P = 0.001）。单独对二级预防试验的分析揭示了类似的统计学显著效果（中风减少32%; P = 0.001）。在一级预防试验中，卒中发生率降低较小，但无显著性（卒中发生率降低15%; P = 0.48）。
结论
现在用于降低胆固醇水平的还原酶抑制剂比以前可用的降胆固醇剂更有效，副作用更少。他们似乎减少中风，最明显的是在患有冠状动脉疾病的患者中，这可能部分是由于降低胆固醇水平对颅外颈动脉粥样硬化的进展和斑块稳定性的影响，或与治疗相关的冠心病事件的显着减少。
BACKGROUND
Epidemiologic evidence and meta-analyses of data from early clinical trials suggest that lowering the levels of cholesterol does not reduce the events of stroke. These analyses have not included more recent clinical trials using reductase inhibitors.
OBJECTIVE
To conduct a meta-analysis of the effect of reducing cholesterol levels on stroke in all reported clinical trials of primary (n = 4) and secondary (n = 8) prevention of coronary heart disease that used reductase inhibitor monotherapy and provided information on incident stroke.
RESULTS
Analysis of combined data from primary and secondary prevention trials showed a highly statistically significant reduction of stroke associated with the use of reductase inhibitor monotherapy (27% reduction in stroke; P = .001). Analysis of secondary prevention trials alone disclosed a similar statistically significant effect (32% reduction in stroke; P = .001). A smaller nonsignificant reduction in stroke was noted in the primary prevention trials (15% reduction in stroke; P = .48).
CONCLUSIONS
Reductase inhibitors now in use for lowering cholesterol levels are more potent and have fewer side effects than the cholesterol-lowering agents previously available. They appear to reduce stroke, most notably in patients with prevalent coronary artery disease, which may be partly due to the effects of lowering the levels of cholesterol on the progression and plaque stability of extracranial carotid atherosclerosis or the marked reduction of incident coronary heart disease associated with treatment.
影响因子：
37.8
作者：
FURBERG, CD;ADAMS, HP;YOUNG, B
通讯作者：
YOUNG, B
DOI：
10.1161/01.atv.14.7.1098
发表时间：
1994-07-01
期刊：
ARTERIOSCLEROSIS AND THROMBOSIS
影响因子：
--
作者：
SHARRETT, AR;PATSCH, W;DAVIS, CE
通讯作者：
DAVIS, CE
中风危险因素的现状。
影响因子：
2.4
作者：
Wolf,PA;Kannel,WB;Verter,J
通讯作者：
Verter,J